



TNX-102 SL

Lead Indication: Fibromyalgia

Additional Indication: Acute Stress Disorder

NASDAQ: TNXP



TNX-102 SL*

Cyclobenzaprine HCl (Protectic[®])

Non-opiate analgesic

A unique, sublingual formulation of cyclobenzaprine designed for bedtime dosing with sublingual delivery and transmucosal absorption, bypassing 1st pass metabolism

Potent binding and antagonist activities at the serotonergic-5-HT_{2A}, adrenergic- α_1 , histaminergic-H₁, and muscarinic-M₁ cholinergic receptors to facilitate restorative sleep

Innovative and proprietary PROTECTIC[®] Rapid drug exposure following once nightly sublingual administration

Differentiators:

Relative to Oral Cyclobenzaprine

- Lower daytime exposure
- Avoids first-pass metabolism
- Reduces risk of pharmacological interference from major metabolite

Relative to Standard of Care

- Potential for better tolerability while maintaining efficacy
- Not scheduled, without recognized abuse potential

Patents Issued

*TNX-102 SL has not been approved for any indication.



Indications with Active Programs

Fibromyalgia

Status: Two statistically significant Phase 3 studies completed; FDA granted Fast Track Designation

- First pivotal Phase 3 study (RELIEF) completed
- Second Phase 3 study (RALLY) missed primary endpoint
- Confirmatory pivotal Phase 3 study (RESILIENT) completed

Next Steps: NDA submission; pre-NDA meetings with FDA complete with alignment on requirements for filing and potential approval

Acute Stress Reaction/ Acute Stress Disorder

- Phase 2 ready investigator-initiated study
- U.S. Department of Defense funded / UNC will perform study

Next Steps: Expect to start Phase 2 in 3Q 2024



About Fibromyalgia

Fibromyalgia is a **chronic pain disorder** resulting from amplified sensory and pain signaling within the CNS – now recognized as ***nociceptive pain***¹⁻⁴

Fibromyalgia is a **syndrome** comprised of the ***symptoms***: chronic widespread pain, ***nonrestorative sleep***, and ***fatigue***



Fibromyalgia is considered a chronic overlapping pain condition (COPC)⁵
- the *only COPC with any FDA-approved drugs*⁶

Fibromyalgia is the prototypic nociceptive syndrome

¹Trouvin AP, et al. *Best Pract Res Clin Rheumatol*. 2019;33(3):101415.

²Fitzcharles MA, et al. *Lancet* 2021;397:2098-110

³Kaplan CM, et al. *Nat Rev Neurol*. 2024 20(6):347-363..

⁴Clauw DJ. *Ann Rheum Dis*. 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.

⁵Maixner W, et al. *J Pain*. 2016;17(9 Suppl):T93-T107.

⁶The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica®); Duloxetine (Cymbalta®); Milnacipran (Savella®)



Fibromyalgia is a Large, Underserved and Dissatisfied Population

- **More than 10 million U.S. adults are affected – predominantly women^{1,2}**
 - Debilitating and life altering condition
 - Significant economic impact
- **Patients are dissatisfied, despite three FDA approved drugs^{3,4}**
 - 85% of patients fail first-line therapy⁵: efficacy variability, tolerability issues especially when used long-term and lack of broad-spectrum activity
 - Typical for patients to rotate between drugs and be on multiple drugs at the same time; 79% of FM patients are on multiple therapies⁵
- **~2.7 million FM patients diagnosed and treated⁶**
 - >22 million prescriptions are issued for the treatment of fibromyalgia (on- and off-label usage) each year^{7,8}
- **No new Rx product since 2009**
- *The treatment objective is to restore functionality and quality of life by broadly improving symptoms while avoiding significant side effects*

¹American College of Rheumatology (www.ACRPatientInfo.org accessed May 7, 2019) – prevalence rate of 2-4% for U.S. adult population (~250 million)

²Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002; diagnosed prevalence rate was 1.1% of adult population or 50% of the prevalent population

³Robinson RL, et al. *Pain Med*. 2012 13(10):1366-76. doi: 10.1111; 85% received drug treatment

⁴The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

⁵EVERSANA primary physician research, May 2024; commissioned by Tonix

⁶EVERSANA analysis of claims database, May 2024; commissioned by Tonix


⁷Product sales derived from IMS MIDAS; IMS NDTI used to factor usage for fibromyalgia; data accessed April 2015.

⁸Market research by Frost & Sullivan, commissioned by Tonix, 2011



Poor Sleep and Pain have Bi-directional Reinforcing Effects¹

- **Poor sleep and pain form a vicious cycle in driving fibromyalgia decompensation**
 - Can't sleep → worse pain / In pain → can't sleep
 - Poor sleep and pain contribute to persistence, chronicity and severity
 - Syndrome includes symptoms of fatigue and brain fog
- **Treating sleep disturbance in fibromyalgia has the potential to break the vicious cycle**
 - Potential to remove an obstacle to recovery
 - Using the right medicine is important – some sedative/hypnotics don't work^{1,2}



¹Moldofsky H, et al. *J Rheumatol*. 1996;23:529–533.
²Grönwald M, et al. *Clin Rheumatol*. 1993;12(2):186–191



Fibromyalgia: Unrefreshing Sleep and Cyclobenzaprine Treatment

- **Non-restorative sleep^{1,2}**
 - Harvey Moldofsky – recognition of unrefreshing/non-restorative sleep:
 - Symptom
 - Potential causative or potentiating factor
- **Cyclobenzaprine³⁻⁹**
 - Potentially the earliest drug studied in fibromyalgia as an oral swallowed agent
 - Studies showed equivocal effects and tolerability issues at “muscle spasm” doses
- **Bedtime, low-dose cyclobenzaprine targeting non-restorative sleep¹⁰⁻¹¹**
 - Recognition of unrefreshing sleep as a target of therapy
 - Primitive oral, swallowed formulation – “flat” pharmacokinetics
- **Bedtime, sublingual transmucosal cyclobenzaprine targeting non-restorative sleep¹²**
 - Dynamic pharmacokinetic profile, rapid absorption, decrease in major metabolite
 - Two studies (Phase 2 and Phase 3) at 2.8 mg; three Phase 3 studies at 5.6 mg.

¹Moldofsky H et al. *Psychosom Med*. 1975. 37:341-51.

²Moldofsky H and Scarisbrick P. *Psychosom Med*. 1976. 38:35-44.

³Bennett RM, et al. *Arthritis Rheum* 1988. 31:1535-42.

⁴Quimby LG, et al. *J Rheumatol Suppl*, 1989 Nov;19:140-3.

⁵Reynolds WJ, et al. *J Rheumatol*. 1991.18:452-4.

⁶Santandrea S, et al. *J Int Med Res*. 1993.21:74-80.

⁷Cantini F, et al. *Minerva Med*. 1994. 85:97-100.

⁸Carette S, et al. *Arthritis Rheum*. 1994. 37:32-40.

⁹Tofferi JK, et al. *Arthritis Rheum*. 2004. 51:9-13.1

¹⁰Iglehart IW. 2003; US Patent 6,541,523.

¹¹Moldofsky et al. *J Rheumatol*. 2011. 38:2653-2663

¹²Lederman S et al. *Arthritis Care Res*. 2023. 75:2359-2368.



Fibromyalgia Program Status

TNX-102 SL

Cyclobenzaprine Protectic®
Sublingual Tablets

Fibromyalgia

**Statistically Significant 2nd Phase 3 Topline Results
Reported 4Q'23**

- First pivotal Phase 3 study (*RELIEF*) reported – December 2020¹
- Second Phase 3 study (*RALLY*) missed primary endpoint – July 2021
- Confirmatory pivotal Phase 3 study (*RESILIENT*) reported – December 2023
- Pre-NDA meetings with FDA completed with alignment on requirements for filing and potential approval – announced July 2024
- Granted FDA Fast Track Designation – July 2024

Next Steps:

- NDA filing expected 2H'24
- FDA decision on NDA approval expected 2025

¹Lederman S, et al. *Arthritis Care Res (Hoboken)*. 2023 Nov;75(11):2359-2368. doi: 10.1002.

Phase 3 RESILIENT Study Population

TNX-102 SL: Phase 3 *RESILIENT* Study Design



General study characteristics:

- Randomized, double-blind, multicenter, placebo-controlled study in fibromyalgia
- 33 U.S. sites enrolled 457 participants with fibromyalgia as defined by 2016 Revisions to the 2010/2011 FM Diagnostic Criteria¹

Primary Endpoint:

- Change from baseline to Week 14 (TNX-102 SL vs. placebo) in weekly averages of daily diary average pain severity score
- **Primary Endpoint, *p-value* = 0.00005**

TNX-102 SL once-daily at bedtime
5.6 mg (2 x 2.8 mg tablets)*

Placebo once-daily at bedtime

14 weeks

ClinicalTrials.gov Identifier: **NCT05273749**

Study Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

Trial ID: TNY-CY-F307 ('RESILIENT')

*Two-week run-in at 2.8 mg dose at bedtime followed by 12 weeks at 5.6 mg dose

¹Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46(3):319-329.

RESILIENT Demographics and Baseline Characteristics



	TNX-102 SL (N=231)	Placebo (N=225)
Age (years)	49.3 (10.45)*	49.5 (11.35)*
Female	224 (97.0%)†	211 (93.8%)†
Hispanic or Latino	36 (15.6%)†	35 (15.6%)†
White	194 (84.0%)†	192 (85.3%)†
Black	32 (13.9%)†	26 (11.6%)†
Pain Score (0-10 NRS)	5.9 (1.05)*	5.9 (1.08)*
Employed Yes	147 (63.6%)†	150 (66.7%)†
FM Duration (years)	8.6 (8.44)*	9.9 (9.53)*
BMI (kg/m²)	31.1 (6.34)*	31.1 (6.32)*

* Mean (standard deviation)

† N (%)

RESILIENT Characteristics of Study Population

Pain Scores

- Patients are asked to record “their average pain” for each day
 - ‘Average’ pain for the day will almost always be lower than ‘worst’ pain for a patient’s day
- Baseline pain for randomization
 - a) A mean pain intensity score ≥ 4 and ≤ 9 on the 11-point (0-10) NRS scale for the 7 days immediately preceding Visit 2, and
 - b) No more than 2 individual days with a score < 4 on the 7 days immediately preceding Visit 2, and
 - c) No score of 10 on any of the 7 days immediately preceding Visit 2, and
 - d) Pain scores recorded on at least 5 out of the 7 days immediately preceding Visit 2
- Mean Pain score for Baseline (BL) for the RESILIENT study was 5.9
 - Using the same method, BL for F304 (RELIEF) was 6.1 and BL for F306 (RALLY) was 6.0
- Breakthrough pain
 - No explicit rescue algorithm
 - 10 participants took an opiate during the study (6 on TNX-102 SL and 4 on placebo)

RESILIENT Study Efficacy Findings



RESILIENT Summary of Primary and Key Secondary Endpoints

Endpoint	P-value	Effect Size (ES)
Primary Endpoint		
Daily Diary Pain ratings	$p = 0.00005$	ES = 0.38
Key Secondary Endpoints		
Patient Global Impression of Change (PGIC), responders	$p = 0.00013$	--
Fibromyalgia Impact Questionnaire – Symptoms domain	$p = 0.000002$	ES = 0.44
Fibromyalgia Impact Questionnaire – Function domain	$p = 0.001$	ES = 0.30
PROMIS Sleep Disturbance instrument	$p = 0.0000001$	ES = 0.50
PROMIS Fatigue instrument	$p = 0.00009$	ES = 0.37
Diary Sleep Quality ratings	$p = 0.0007$	ES = 0.32

*In order of statistical serial gate-keeping hierarchy (or, “waterfall”) to control overall Type 1 error

**Statistical significance met




RESILIENT Primary Outcome Measure

Reduction in Widespread Pain



Weekly Average of Daily Diary NRS Ratings of Average Pain Over Prior 24 Hours




*p<0.01; **p<0.001; ***p<0.0001

Week 14 LS mean (SE) change from baseline for TNX-102 SL -1.82 (0.12) and for placebo -1.16 (0.12); LSMD from placebo -0.65 (0.16); **p=0.00005#**

#Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction. Abbreviations: LS, least squares; LSMD, least squares mean difference; NRS, numerical rating scale; SE, standard error



RESILIENT Continuous Pain Responder Graph




#Analyses: Pearson's Chi Squared test for equality of proportions
 Abbreviations: CI, confidence interval; DIP, difference in proportions
 ^pre-specified analyses but not key secondary analyses

RESILIENT Patient Global Impression of Change

Key Secondary Outcome Measure



Patient Global Impression of Change Responder Analysis




*p<0.01; **p<0.001

Week 14 TNX-102 SL responders 35.1%, and placebo responders 19.1%; difference in proportions (95% CI) 16% (7.9%, 24.0%); **p=0.00013**#

#Based on a Pearson Chi-Squared with differences in proportions 95% CIs from difference in proportions Z-test
Responders defined as subject that reply 'very much improved' or 'much improved' at Week 14; all others are non-responders
CI, confidence interval

RESILIENT FIQ-R Symptoms Domain

Key Secondary Outcome Measure



Week 14 LS mean (SE) change from baseline for TNX-102 SL -16.0 (1.17) and for placebo -8.4 (1.17); LSMD from placebo -7.7 (1.62); **p=0.000002**[#]


[#]Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.

RESILIENT FIQ-R Function Domain

Key Secondary Outcome Measure



Fibromyalgia Impact Questionnaire – Revised (FIQ-R) Function Domain




Week 14 LS mean (SE) change from baseline for TNX-102 SL -12.2 (1.19) and for placebo -6.8 (1.21); LSMD from placebo -5.4 (1.66); **p=0.001**[#]

[#]Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.

RESILIENT PROMIS Sleep Disturbance Inventory

Key Secondary Outcome Measure




Week 14 LS mean (SE) change from baseline for TNX-102 SL -8.4 (0.57) and for placebo -4.2 (0.56); LSMD from placebo -4.2 (0.79); **p=0.0000001**#

#Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.

RESILIENT PROMIS Fatigue Inventory

Key Secondary Outcome Measure



Week 14 LS mean (SE) change from baseline for TNX-102 SL -7.2 (0.55) and for placebo -4.2 (0.56); LSMD from placebo -3.0 (0.77); **p=0.00009#**


#Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.

RESILIENT Sleep Quality by Daily Diary

Key Secondary Outcome Measure



Weekly Average of Daily Diary NRS Ratings of Prior Night Sleep Quality



Week 14 LS mean (SE) change from baseline for TNX-102 SL -1.77 (0.12) and for placebo -1.20 (0.12); LSMD from placebo -0.57 (0.17); **p=0.0007#**

#Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.

RESILIENT Summary of Primary Endpoint and Key Secondary Efficacy Endpoints

Fibromyalgia is a *syndrome* composed of *symptoms*

- Widespread pain
- Fatigue
- Sleep disturbance

Efficacy across symptoms of pain, fatigue and sleep

- Pain (primary endpoint, daily pain diary): p -value of 0.00005
- Fatigue (PROMIS fatigue): p -value of 0.00009
- Sleep (PROMIS sleep disturbance): p -value of 0.0000001


Conclusion: TNX-102 SL has “broad spectrum” or “syndromal activity”

- Broad spectrum: across several symptoms
- Syndromal: improves the syndrome (most of the symptoms)
- Potential for a broad-spectrum drug to reduce the use of multiple drugs or “polypharmacy”



RESILIENT: CSFQ-14 Females

Pre-specified exploratory endpoint



Changes in Sexual Functioning Questionnaire short form (CSFQ-14) was a safety measure in the study

- In females, CSFQ-14 total score improved (indicating better sexual functioning) to a greater extent in the TNX-102 SL group compared with placebo, p=0.010
- Potential tolerability advantage over pharmacotherapeutics with potent serotonin reuptake inhibition

ANCOVA analysis: comparison between groups (TNX-102 SL 5.6 mg vs. Placebo)
 Red Diamond refers to treatment differences with p < 0.05, not corrected for multiple comparisons

RESILIENT: FIQR Individual Items¹

Affective Symptoms, Sensory Sensitivity, Cognition, and Energy

Pre-specified exploratory endpoint



CNS PORTFOLIO

Selected Fibromyalgia Impact Questionnaire-Revised Symptoms Domain Item Scores Pre-specified exploratory endpoints

FIQ-R Item	Week 14 LS Mean (SE) Difference from Placebo [#]	95% Confidence Interval [#]	P-value [^]	Effect Size
Please rate your level of... (past 7 days)				
Depression	-0.8 (0.21)	-1.2, -0.6	<0.001	0.35
Anxiety	-0.8 (0.24)	-1.2, -0.3	0.001	0.30
Sensitivity to... [*]	-0.6 (0.24)	-1.0, -0.1	0.020	0.22
Memory problems	-0.8 (0.23)	-1.2, -0.3	0.001	0.31
Energy	-0.8 (0.23)	-1.2, -0.3	<0.001	0.31

*...loud noises, bright lights, odors, and cold

¹FIQR=Fibromyalgia Impact Questionnaire- Revised

[#]Mixed model repeated measures analysis (no imputation); fixed categorical effects of treatment, site, study week, and treatment x study week interaction; fixed covariates of baseline value and baseline value x study week interaction


[^]Uncorrected for multiple comparisons

RESILIENT: Beck Depression Inventory-II Pre-specified Exploratory Endpoint



	Placebo Mean (SD)	Placebo LS MCFB (SE)	TNX Mean (SD)	TNX LS MCFB (SE)	Difference in LS Means (SE)	95% CI for Difference	P-value	Effect Size
Baseline	10.0 (6.72)		9.6 (6.32)					
Week 14		-2.0 (0.35)		-3.4 (0.35)	-1.4 (0.49)	-2.3, -0.4	0.005 [#]	0.27

- Greater reduction in total BDI-II score in TNX-102 SL group over placebo at Week 14 with $p=0.005^{\#}$, effect size of 0.27
 - Also separated, with $p<0.01^{\#}$, at Week 2 when on TNX-102 SL 2.8 mg first two weeks
 - And separated, with $p<0.001^{\#}$, at Week 6



[#]Uncorrected for multiple comparisons
SE=standard error; SD=standard deviation



RESILIENT: Summary of Baseline Depression BDI-II and FIQR Item

- While the rate of current MDE diagnosis was ~2% of the ITT, ~25% ITT had experienced a lifetime MDE, and ~47% reported past 6 month depression on FM Dx*
- Also, about 25% of the ITT enrolled on concomitant antidepressant or buspirone
- By end of treatment (Week 14), there was a greater reduction in depression severity by total BDI-II score in TNX-102 SL group compared with placebo (p=0.005)
 - And greater reduction in FIQR items for depression (p<0.001), anxiety (p=0.001), and sensory sensitivity (p=0.020) in the TNX-102 SL group compared with placebo
 - The FIQR memory item, a measure of cognitive impairment in FM, was more improved in the TNX-102 SL group than placebo (p=0.001)
 - The FIQR energy item, another indicator of less fatigue in FM, was also more improved in the TNX-102 SL group than placebo (p<0.001)
- Cohen's *d* effect sizes were between 0.27 and 0.35 for all Week 14 outcomes above except sensory sensitivity

Abbreviations: BDI-II, Beck Depression Inventory-II; Dx, diagnosis; FIQR, Fibromyalgia Impact Questionnaire-Revised; FM, fibromyalgia; ITT, Intention-to-Treat

*Wolfe F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Semin Arthritis Rheum.* 2016; 46(3):319-329.

RESILIENT Summary of Efficacy



Primary Pain, and Key Secondaries

- Pain (primary endpoint, daily pain diary): p -value = 0.00005
- Fatigue (PROMIS fatigue): p -value = 0.00009
- Sleep (PROMIS sleep disturbance): p -value = 0.0000001
- Global (PGIC) p -value = 0.00013
- Symptoms (FIQR Symptoms) p -value = 0.000002
- Function (FIQR Function) p -value = 0.001

Exploratory endpoints

- Female Sexual Function (CSFQ) p -value = 0.010
- Depression (BDI-II) p -value < 0.001
- Depression (FIQR): p -value < 0.001
- Anxiety (FIQR): p -value = 0.001
- Sensitivity to environment* (FIQR): p -value = 0.020
- Memory (FIQR) : p -value = 0.001
- Energy (FIQR): p -value < 0.001

*loud noises, bright lights, odors, and cold

RESILIENT Summary of Efficacy



Conclusion: TNX-102 SL has “broad spectrum” or “syndromal activity”

- Broad spectrum: across several symptoms
- Syndromal: improves the syndrome (most of the symptoms)
- Potential for a broad-spectrum drug to reduce the use of multiple drugs or “polypharmacy”

RESILIENT Study Safety Findings

RESILIENT Subject Disposition



	<u>Placebo</u>	<u>TNX-102 SL</u>	<u>Total</u>
Randomized	226	231	457
Completed	179 (79.2%)	187 (81.0%)	366 (80.1%)
Discontinued	47 (20.8%)	44 (19.0%)	91 (19.9%)
Adverse Event	8 (3.5%)	14 (6.1%)	22 (4.8%)
Lack of Efficacy	8 (3.5%)	2 (0.9%)	10 (2.2%)
Investigator Decision	2 (0.9%)	0 (0.0%)	2 (0.4%)
Withdrew Consent	16 (7.1%)	14 (6.1%)	30 (6.6%)
Lost to Follow Up	10 (4.4%)	10 (4.3%)	20 (4.4%)
Pregnancy	0 (0.0%)	1 (0.4%)	1 (0.2%)
Non-Compliance	2 (0.9%)	3 (1.3%)	5 (1.1%)
Other	1 (0.4%)	0 (0.0%)	1 (0.2%)

RESILIENT Prior Medication Use



Summary of Lifetime and Prior Fibromyalgia Pharmacotherapy*

	TNX-102 SL N=231	Placebo N=226	Total* N=457
At least one lifetime medication	124 (53.7%)	133(58.8%)	257 (56.2%)
Gabapentin/Pregabalin	72 (31.2%)	75 (33.2%)	147 (32.2%)
Gabapentin	46 (19.9%)	50 (22.1%)	96 (21.0%)
Pregabalin**	46 (19.9%)	45 (19.9%)	91 (19.9%)
Antidepressants	60 (26.0%)	66 (29.2%)	126 (27.6%)
Duloxetine**	47 (20.3%)	52 (23.0%)	99 (21.7%)
Amitriptyline	12 (5.2%)	13 (5.8%)	25 (5.5%)
Milnacipran**	5 (2.2%)	10 (4.4%)	15 (3.3%)

*Safety population, shown are medicines >3% reported in any group

**Indicated for management of fibromyalgia

RESILIENT Washout Medications



Summary of Prior Washout Medications (at least two patients)*

	TNX-102 SL N=231	Placebo N=226	Total* N=457
At least one washout medication	14 (6.1%)	12 (5.3%)	26 (5.7%)
Nervous System Drug	10 (4.3%)	10 (4.4%)	20 (4.4%)
Gabapentin	5 (2.2%)	1 (0.4%)	6 (1.3%)
Amphetamine (different salts)	1 (0.4%)	2 (0.9%)	3 (0.7%)
Duloxetine**	1 (0.4%)	2 (0.9%)	3 (0.7%)
Trazodone	1 (0.4%)	2 (0.9%)	3 (0.7%)
Amitriptyline	0 (0.0%)	2 (0.9%)	2 (0.4%)

*Safety population

**Indicated for management of fibromyalgia



RESILIENT Safety Summary

Among participants randomized to TNX-102 SL and to placebo, 81.0% and 79.6%, respectively, completed the study
TNX-102 SL was generally well tolerated with an adverse event (AE) profile comparable to prior fibromyalgia studies

- No new safety signals were observed
- AE-related study discontinuations occurred in 6.1% and 3.6% of patients in the TNX-102 SL and placebo groups, respectively
- Events rated as mild or moderate made up 97.2% of AEs on placebo and 99.1% on TNX-102 SL
- As observed in prior studies with TNX-102 SL, oral administration site AEs were higher in TNX-102 SL than placebo, 42.9% and 10.2%, respectively
 - Most common oral AEs were oral hypoaesthesia, product taste abnormal, oral paraesthesia, and tongue discomfort (see table on next slide)
 - Nearly all of these common oral AEs were temporally related to dosing and lasted <60 minutes
- Serious Adverse Events (SAEs)
 - Three placebo participants experienced an SAE:
 - 1. Pneumonia, 2. Muscular weakness, and 3. Hypertension/Angina/Coronary Artery Disease
 - Two TNX-102 SL participants experienced an SAE
 - 1. Renal carcinoma deemed not related to study drug
 - 2. Acute pancreatitis with onset 14 days after completion of treatment phase, deemed ‘possibly related’* to study drug
 - Outcome: ‘Recovered/Resolved’
 - *Note: participant was non-compliant with end of treatment study visits, and the last dose before onset of SAE was not known at the time that relationship with study drug was assessed by Investigator and Sponsor




Treatment-Emergent Adverse Events (TEAEs) at Rate of $\geq 3\%$ in Either Treatment Group

System Organ Class Preferred Term	TNX-102 SL N=231	Placebo N=226	Total* N=457
Systemic Adverse Events			
COVID-19	10 (4.3%)	7 (3.1%)	17 (3.7%)
Somnolence	7 (3.0%)	3 (1.3%)	10 (2.2%)
Headache	7 (3.0%)	4 (1.8%)	11 (2.4%)
Oral Cavity Adverse Events			
Hypoaesthesia oral	55 (23.8%)	1 (0.4%)	56 (12.3%)
Product taste abnormal	27 (11.7%)	2 (0.9%)	29 (6.3%)
Paraesthesia oral	16 (6.9%)	2 (0.9%)	18 (3.9%)
Tongue discomfort	16 (6.9%)	0 (0.0%)	16 (3.5%)

RESILIENT Analysis by Sensory Adverse Events (AEs) TNX-102 SL group divided for presence/absence of 3 sensory AEs



- AEs of oral numbness, oral tingling, and bitter aftertaste named ‘Sensory AEs’*
- Graph shows negligible advantage for presence of sensory AEs
- At Week 14:
 - TNX-NoSensory v Placebo
 - Diff in LS Mean (SE): -0.62 (0.179)
 - $p < 0.001$
 - TNX-SensoryAEs v Placebo
 - Diff in LS Mean (SE): -0.72 (0.239)
 - $p < 0.003$
 - TNX-NoSensory v TNX-SensoryAEs
 - Diff in LS Mean (SE): -0.10 (0.254)
 - $p < 0.701$
 - Both TNX-102 SL subgroups show significantly greater pain reduction than placebo
 - The two TNX-102 SL subgroups do not significantly differ from each other



*Preferred Terms: Hypoaesthesia oral, Paraesthesia oral, Product taste abnormal

RESILIENT Safety, Continued

No Signals for Clinically Meaningful Changes in Systolic or Diastolic Blood Pressure or in Weight

*No clinically meaningful difference in mean **systolic blood pressure** between groups*

Week 14 mean (SD) change from baseline:

TNX-102 SL = 0.7 (12.38) mmHg

Placebo = 0.5 (10.42) mmHg

*No clinically meaningful difference in mean **diastolic blood pressure** between groups*

Week 14 mean (SD) change from baseline:

TNX-102 SL = 1.1 (8.60) mmHg

Placebo = 0.2 (8.22) mmHg


*No clinically meaningful difference in mean **weight** between treatment groups*

Week 14 mean (SD) change from baseline:

TNX-102 SL = 0.02 (2.940) kg

Placebo = 0.20 (2.932) kg

RESILIENT Systolic blood pressure Safety Measure



No clinically meaningful difference in mean systolic blood pressure between groups


Week 14 mean (SD) change from baseline:

TNX-102 SL = 0.7 (12.38) mmHg

Placebo = 0.5 (10.42) mmHg

Horizontal lines are the mean for each group; boxes are the 25th and 75th percentiles; and vertical lines begin and end at the 5th and 95th percentiles.

RESILIENT Diastolic blood pressure Safety Measure



No clinically meaningful difference in mean diastolic blood pressure between groups


Week 14 mean (SD) change from baseline:

TNX-102 SL = 1.1 (8.60) mmHg

Placebo = 0.2 (8.22) mmHg

Horizontal lines are the mean for each group; boxes are the 25th and 75th percentiles; and vertical lines begin and end at the 5th and 95th percentiles.

RESILIENT Weight Safety Measure



No clinically meaningful difference in mean weight between treatment groups

Week 14 mean (SD) change from baseline:

TNX-102 SL = 0.02 (2.940) kg

Placebo = 0.20 (2.932) kg

■ Placebo (N=226) ■ TNX-102 SL (N=231)

Horizontal lines are the mean for each group; boxes are the 25th and 75th percentiles; and vertical lines begin and end at the 5th and 95th percentiles.

Fibromyalgia Market Characteristics



Fibromyalgia: Market Characteristics

Prevalence

- One of the more common chronic pain disorders (2-4% of US Population)¹

Diagnosed population

- Large population but underdiagnosed² relative to prevalence rate
- Majority receive drug treatment³

Treatment Pattern

- Polypharmacy the norm - average 2.6 drugs/patient³
- Rotation through therapy common: average ~5 drugs/year³
- Estimated that >22 million prescriptions are issued for the treatment of fibromyalgia (on- and off-label usage) each year^{4,5}

Unmet Need

- Majority of patients do not respond or cannot tolerate therapy⁶

¹American College of Rheumatology (www.ACRPatientInfo.org accessed May 7, 2019) – prevalence rate of 2-4% for U.S. adult population (~250 million)

²Vincent et al., 2013; diagnosed prevalence rate was 1.1% of adult population or 50% of the prevalent population

³Robinson, et al., 2012; 85% received drug treatment

⁴Vincent et al, Arthritis Care Res 2013;65:786

⁵Product sales derived from IMS MIDAS; IMS NDTI used to factor usage for fibromyalgia; data accessed April 2015.


⁶Market research by Frost & Sullivan, commissioned by Tonix, 2011



Fewer than Half of Those Treated for Fibromyalgia Receive Sustained Benefit from the Three FDA-Approved Drugs¹

- The treatment objective is to **restore functionality** and **quality of life** by broadly improving symptoms while avoiding significant side effects
- The majority fail therapy due to **lack of a response** or **poor tolerability**²

Treated Population



¹ The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

² Market research by Frost & Sullivan, commissioned by Tonix (2011)



Current FDA-Approved Fibromyalgia Drugs were Repurposed¹

Human investigation was required to find drugs that improve pain in fibromyalgia

- No current product addresses pain, poor sleep and fatigue

Drug		Lyrica® - Pfizer	Cymbalta® - Lilly Savella® - AbbVie
Initial Indication Sought		Epilepsy	Depression
Class		Gabapentinoid	SNRI
Mechanism		Slow neuron firing	Block NE reuptake
Fibromyalgia Activity	Pain	+	+
	Sleep	+	-
	Fatigue	-	+
Tolerability Issues	Sleep	-	+
	Fatigue	+	-
		Weight gain	Blood Pressure increases
			Sexual function impairment
			GI issues

¹The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

Large Need for New Fibromyalgia Therapies that Provide Broad Symptom Improvement with Better Tolerability

- Currently-approved medications may have side effects that limit long-term use¹
 - Many patients skip doses or discontinue altogether within months of treatment initiation
- Medication-related side effects may be similar to fibromyalgia symptoms
- High rates of discontinuation, switching and augmentation
 - Attempt to treat multiple symptoms and/or avoid intolerable side effects
 - Average of 2-3 medications used simultaneously²
 - The typical patient has tried six different medications³
- Substantial off-label use of narcotic painkillers and prescription sleep aids³
 - Among those diagnosed, more than one-third have used prescription opioids as a means of treatment⁴
- TNX-102 SL is a non-opioid, centrally-acting analgesic that could provide a new therapeutic option for fibromyalgia patients

¹ Nuesch et al, Ann Rheum Dis 2013;72:955-62.

² Robinson RL et al, Pain Medicine 2012;13:1366.

³ Patient Trends: Fibromyalgia", Decision Resources, 2011.

⁴ Berger A, Dukes E, Martin S, Edelsberg J, Oster G, Int J Clin Pract, 2007; 61(9):1498-1508.





TNX-102 SL Showed Broad-Spectrum Activity and was Well Tolerated

		Lyrica®	Cymbalta® Savella®	TNX-102 SL
Activity	Pain	YES	YES	YES
	Sleep	YES	-	YES
	Fatigue	-	YES	YES
Systemic Tolerability Issues	Insomnia	-	+	-
	Fatigue	+	-	-
	Weight	+	-	-
	Blood Pressure	-	+	-
	Sexual function	-	+	-
	GI issues	-	+	-

- TNX-102 SL showed activity in all three measures of pain, sleep, and fatigue
- TNX-102 SL is not associated with any of the commonly reported side effects



~50% of U.S. Fibromyalgia Patients are on Medicare: Prescription Coverage in Medicare Stands to Benefit from Changes in IRA


Approximately 50% of fibromyalgia patients are on Medicare

- EVERSANA analysis of claims database consisting of 2.2M patients, for which 1.2M claims were submitted throughout March 2002-March 2023¹

Beneficial Changes in 2025 to Medicare Part D through Inflation Reduction Act (IRA)²

- Medicare prescription payment plan to offer enrollees the option to pay out-of-pocket prescription drug costs in the form of capped monthly installment payments instead of all at once at the pharmacy
- Annual out-of-pocket costs will be capped at \$2,000 in year 2025
- Will replace the existing Coverage Gap Discount Program, which sunsets as of January 1, 2025

Fibromyalgia Patients by Coverage¹




¹EVERSANA analysis of claims database, May 2024; commissioned by Tonix

²Source: [Final CY 2025 Part D Redesign Program Instructions Fact Sheet | CMS](#)


Prescribers Interviewed are Broadly Dissatisfied with Available Fibromyalgia Medications: Results of Primary Research¹



Perspectives on FM Therapies from Prescribers Interviewed		
Drug	Positives	Negatives
Duloxetine (<i>Cymbalta, generic</i>)	<ul style="list-style-type: none"> Relatively high efficacy (compared to alternatives) Can be titrated slowly from 20mg to 120mg 	<ul style="list-style-type: none"> Tolerability issues: worsening depression, insomnia Seldom used as a monotherapy; often requires adjunct
Pregabalin (<i>Lyrica, generic</i>)	<ul style="list-style-type: none"> Relatively high efficacy (compared to alternatives) Can often be safely combined with other medications 	<ul style="list-style-type: none"> Suboptimal for long-term use (e.g., weight gain) Schedule V status makes some HCPs more cautious to Rx
Savella (<i>milnacipran</i>)	<ul style="list-style-type: none"> Offers another option if patient fails Cymbalta or Lyrica 	<ul style="list-style-type: none"> Subpar efficacy does not counterbalance tolerability issues High cost and access constraints (~\$50/month)
Cyclobenzaprine (<i>Flexeril, generic; oral formulation, off-label</i>)	<ul style="list-style-type: none"> Active for initiating and sustaining sleep; can be titrated up Active for pain driven by stiffness and muscle spasms 	<ul style="list-style-type: none"> Mixed perspectives on pain benefit independent of sleep Suboptimal long-term results as efficacy wanes



85% of patients (avg) fail first line therapy



79% of FM patients (avg) are on multiple therapies

¹EVERSANA primary physician research, May 2024; commissioned by Tonix

Opportunity for a New, Unique Fibromyalgia Treatment Option: Results of Primary Research from EVERSANA^{1,2}



FM Landscape

- Prescribers indicate a **very high unmet need** in FM (ranked ≥ 4.0 on a 5-point scale)
- Prescribers report there is **no standard of care in FM**, employ an **individualized approach** based on symptomology
- No new treatments approved since 2009
- Prescribers report minimal promotional activities by any pharmaceutical company
- Highly concentrated prescriber base with 50% of patients treated by ~16k physicians



Physician Primary Market Research

- **Physicians reacted positively to the efficacy and safety profile of TNX-102 SL (based on Phase 3 Study results)**
- Median interest = 4.0 on a 5-point scale
- Driving attributes included **strong efficacy, safety and tolerability**
- Unique & differentiating efficacy features included improvements in **sleep and fatigue**



Anticipated Use

- **Physicians indicated intended use in 40% of their FM patients**
- Majority of respondents indicated TNX-102 SL would be their first choice, if accessible
- Physicians surveyed indicated they are well-equipped to deal with access restrictions including prior authorizations and step-edits


¹ EVERSANA primary physician research, May 2024; commissioned by Tonix

² EVERSANA analysis of claims database, May 2024; commissioned by Tonix

Many Fibromyalgia Patients are Prescribed Off-Label Drugs; ~53% FM Patients Prescribed Opioids Off-Label^{1,2}



% FM Patients (after index³ date)



- Anti-convulsant
- SNRI
- Tricyclic antidepressant
- Opiate
- NSAID
- Muscle relaxant

¹ 2022-2023
² EVERSANA analysis of claims database, May 2024; commissioned by Tonix
³ Index date refers to date when ICD10 code was entered into database



Potential for Tonix to Launch and Market TNX-102 SL

Decline in personal promotion (“Detailing”) of prescription drugs

- The pandemic accelerated transition to non-personal promotion
 - Omnichannel is more important and more sophisticated
 - Tele-sales
 - Digital
 - Direct mail
- Growth in need to support patients with payers to seek reimbursement

Fibromyalgia experts are a subset of Rheumatologists

- New prescriptions for fibromyalgia drugs originate in a subset of doctors
 - Refills may be written by general practitioners

Channels for distribution of prescription drugs are evolving

- Growth of specialty pharmacies who distribute products by mail



Planning for TNX-102 SL Launch and Marketing

Several companies that successfully developed CNS drugs have launched them

- Big Pharma wants the commercial launch de-risked before acquisition (e.g., Nurtec®)

Company		Mkt Cap ¹	Product	Indication	FDA Approval	Exit
Axsome	AXSM	\$3.5 B	Auvelity®	Depression	8/2022	
Biohaven	BHVN	\$3.0 B	Nurtec®	Migraine	2/2020	Sold to PFE for \$12 B in Oct 2022
IntraCellular	ITCI	\$7.2 B	Caplyta®	Schizophrenia	12/2019	
Supernus	SUPN	\$1.4 B	Oxtella-XR®	Seizures	1/2019	
Neurocrine	NBIX	\$13.6 B	Ingrezza®	Tardive Dyskinesia	4/2017	
Acadia	ACAD	\$2.5 B	Nuplazid®	Parkinson's psychosis	4/2016	

To prepare for the launch of TNX-102 SL, Tonix acquired two marketed Rx drugs: Zembrace® and Tosymra®


- Both are indicated for the acute treatment of migraine

¹Accessed June 7, 2024

About Cyclobenzaprine and TNX-102 SL



Cyclobenzaprine Long-Term Utilization



- **Flexeril® approved in 1977 by Merck for the treatment of muscle spasm**
 - 10 mg T.I.D. for acute use (2-3 weeks)
 - Original NDA included “8 long term safety studies in which patients with various neurologic disorders received cyclobenzaprine up to 80 mg per day for 1 month up to 3 years.”¹
- **6 published studies in fibromyalgia**²⁻⁸
 - N=246, placebo controlled, 4-24 week treatment period
 - Generally well tolerated, no new or unexpected AEs
- **Extensive safety record in humans for over 30 years**
 - Widely used in the U.S., ~20 million prescriptions and ~ 1 billion tablets dispensed *per year*⁹
 - Chronic cyclobenzaprine use is common (~12% of users)⁹
- **Post-marketing surveillance program**¹
 - 7,607 patients included 297 patients treated with 10 mgs for ≥ 30 days
 - Incidence of most common AEs was much lower than in controlled studies

¹1999 Merck OTC AdCom Briefing Package

²Bennett RM, et al. *Arthritis Rheum* 1988. 31:1535–42.

³Quimby LG, et al. *J Rheumatol Suppl*, 1989 Nov;19:140–3.

⁴Reynolds WJ, et al. *J Rheumatol*. 1991.18:452–4.

⁵Santandrea S, et al. *J Int Med Res*. 1993.21:74–80.

⁶Cantini F, et al. *Minerva Med*. 1994. 85:97–100.

⁷Carette S, et al. *Arthritis Rheum*. 1994. 37:32–40.


⁸Tofferi JK, et al. *Arthritis Rheum*. 2004. 51:9–13.1

⁹IMS report 2011 of cyclobenzaprine use in 2009 – Data on File



TNX-102 SL: Sublingual Administration and Transmucosal Delivery


- Advantages of the sublingual route
- Faster absorption provides PK that is ideal for bedtime dosing
- Bypasses “first-pass” hepatic metabolism
- Reduced metabolism of parent CBP to active metabolite norcyclobenzaprine (nCBP)



Formulation with Base Increases Systemic Absorption of Sublingual Cyclobenzaprine¹



Concentration gradient increases diffusion of free base across oral mucosa (Le Chatelier's Principle)




¹US Patent applications 13/918,692, 14/214,433 and 14/776,624 - Eutectic Formulations



TNX-102 SL: Proprietary Eutectic Formulation

- Proprietary Cyclobenzaprine HCL Eutectic Mixture Stabilizes Sublingual Tablet Formulation




¹ U.S. Patent issued May 2, 2017

TNX-102 SL: Cyclobenzaprine Detected in Plasma Within Minutes Following Sublingual Administration



Plasma Concentration Versus Time of TNX-102 SL Compared to Cyclobenzaprine IR





TNX-102 SL: Single Dose PK Differentiation from Oral IR CBP

TNX-102 SL 2.8 mg v. Oral IR CBP 5 mg: Single Dose Pharmacokinetics

Parameter	TNX-102 SL 2.8 mg	Oral IR CBP 5 mg	TNX-102 SL Compared to Oral IR
	Cyclobenzaprine		
Absorption Lag Time	0.050 hr (3 min)	0.622 hr (37 min)	12x faster
Relative Bioavailability	154%	-	54% higher
C_{max}	3.41 ng/mL	4.26 ng/mL	20% lower
AUC₀₋₄₈	57.4 ng•hr/mL	69.5 ng•hr/mL	17% lower
	Norcyclobenzaprine		
C_{max}	0.81 ng/mL	1.71 ng/mL	53% lower
AUC₀₋₄₈	30.5 ng•hr/mL	58.6 ng•hr/mL	48% lower
	Cyclobenzaprine/Norcyclobenzaprine		
Ratio AUC₀₋₄₈	1.88	1.18	59% higher

PK = pharmacokinetics
 IR = immediate release
 CBP = cyclobenzaprine
 C_{max} = maximum concentration
 AUC = Area under the curve



TNX-102 SL: Multi-Dose PK Differentiation from Simulated Oral IR CBP

TNX-102 SL: Proprietary sublingual formulation of cyclobenzaprine (CBP) with transmucosal absorption

- Rapid systemic exposure
- Increases bioavailability during sleep
- Avoids first-pass metabolism
- Lowers exposure to long-lived active major metabolite, norcyclobenzaprine (norCBP)


CBP undergoes extensive first-pass hepatic metabolism when orally ingested

- Active major metabolite, norCBP


PK = pharmacokinetics
 IR = immediate release
 CBP = Cyclo = cyclobenzaprine
 Nor = norCBP = norcyclobenzaprine

Steady State Pharmacokinetics (after 20 days dosing)

Day 20 TNX-102 SL 5.6 mg v. Simulated Oral IR 5 mg



Day 20 TNX-102 SL 5.6 mg v. Simulated Oral IR 10 mg



Multi-Functional Mechanism Involves Antagonism at Four Neuronal Receptors



Active ingredient, cyclobenzaprine, interacts with four receptors

- Antagonist at 5-HT_{2A} receptors
 - Similar activity to trazodone and Nuplazid[®] (pimivanserin)
- Antagonist at α_1 -adrenergic receptor
 - Similar activity to Prazosin[®] (prazosin)
- Antagonist at histamine H₁ receptors
 - Similar activity to Benadryl[®] (diphenhydramine) and hydroxyzine
- Antagonist at muscarinic M₁ receptors
 - Similar activity to Benadryl[®] (diphenhydramine), Prozac[®] (fluoxetine), Paxil[®] (paroxetine), Zyprexa (olanzapine) and Seroquel[®] (quetiapine).



Cyclobenzaprine Binding Affinities for Receptor and Transporter

	H ₁	5-HT _{2A}	α _{1A}	α _{1B}	M ₁	SERT	NET
Cyclobenzaprine (CBP)	1.2	5.4	7.1	8	8.4	29	39
Norcyclobenzaprine (nCBP)	17.8	38	82	71	155	461	12.8

CBP/nCBP Activity






Cyclobenzaprine Effects on Nerve Cell Signaling

Cyclobenzaprine is a multi-functional drug – SNARI

- inhibits serotonin and norepinephrine reuptake
- blocks serotonin 5-HT_{2A} and norepinephrine_{α1} receptors



SNARI = Serotonin and Norepinephrine reuptake Inhibitor and Receptor Antagonist



TNX-102 SL: No Recognized Abuse Potential in Clinical Studies

Active ingredient is cyclobenzaprine, which is structurally related to tricyclic antidepressants

- Cyclobenzaprine interacts with receptors that regulate sleep quality: 5-HT_{2A}, α 1-adrenergic and histamine H₁ receptors
- Cyclobenzaprine does NOT interact with the same receptors as traditional hypnotic sleep drugs, benzodiazepines or non- benzodiazepines that are associated with retrograde amnesia
- Cyclobenzaprine-containing product was approved 40 years ago and current labeling (May 2016) indicates no abuse or dependence concern

TNX-102 SL NDA can be filed without drug abuse and dependency assessment studies

- April 2017 meeting minutes from the March 2017 FDA meeting



TNX-102 SL: Sublingual Formulation is Designed for Bedtime Administration

TNX-102 SL: Proprietary sublingual formulation of cyclobenzaprine (CBP) with transmucosal absorption

- Innovation by design with patent protected CBP/mannitol eutectic
- Rapid systemic exposure
- Increases bioavailability during sleep
- Avoids first-pass metabolism
- Lowers exposure to long-lived active major metabolite, norcyclobenzaprine (norCBP)

CBP undergoes extensive first-pass hepatic metabolism when orally ingested

- Active major metabolite, norCBP1
- Long half-life (~72 hours)
- Less selective for target receptors (5-HT_{2A}, α 1-adrenergic, histamine H₁)
- More selective for norepinephrine transporter and muscarinic M₁

Multi-functional activity suggests potential for other indications

- TNX-102 SL was developed for the management of fibromyalgia (Phase 3)
- Sleep quality is a problem in other conditions



TNX-102 SL: Patents and Patent Applications

- **U.S. Composition:***
 - A 75:25 cyclobenzaprine HCl - mannitol eutectic (dependent claims add a basifying agent).
 - 5 US Patents (Expire November 2034)
 - 1 Pending US Application (Would expire November 2034)
 - A composition of a cyclobenzaprine HCl and a basifying agent suitable for sublingual absorption.
 - 1 Pending US Application (Would expire June 2033)
- **U.S. Methods of Use* (Specific Indications):**
 - Fibromyalgia
 - Pain, Sleep Disturbance, Fatigue
 - 1 Pending US Application (Would expire December 2041)
 - Early Onset Response
 - 1 Pending US Provisional Application (Would expire December 2044)
 - Depressive Symptoms
 - 1 Pending US Application (Would expire March 2032)
 - Sexual Dysfunction
 - 1 Pending US Application (Would expire October 2041)
 - PASC
 - 1 Pending US Application (Would expire June 2043)
 - PTSD
 - 1 US Patent (Expires November 2030)
 - Agitation (Dementia)
 - 1 US Patent (Expires December 2038)
 - 1 Pending US Application (Would expire December 2038)
 - Alcohol Use Disorder
 - 1 Pending US Application (Would expire November 2041)
- **Foreign Filings**
 - Corresponding foreign patents have been filed and some have issued:
 - Composition (25 patents, 3 allowed applications, 16 pending applications)
 - Methods of Use (9 patents, 54 pending applications)

*US Patents: Issued: US Patent Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321. Pending: US Patent Application Nos. 13/918,692; 18/385,468; 13/412,571; 18/265,525; 63/612,352; 18/382,262; 18/037,815; 17/226,058; 18/212,500.

TNX-102 SL for Other Indications In Development: *Acute Stress Disorder*



Acute Stress Reaction (ASR)/ Acute Stress Disorder (ASD)

ASR/ASD are acute stress conditions resulting from trauma which can affect both civilian and military populations.

Large unmet need:

- According to National Center for PTSD, about 60% of men and 50% of women in the US are exposed least one traumatic experience in their lives¹
- In the US alone, one-third of emergency department visits (40-50 million patients per year) are for evaluation after trauma exposures²

Current standard of care:

- No medications are currently available at or near the point of care to treat patients suffering from acute traumatic events and support long-term health

¹National Center for PTSD. How Common is PTSD in Adults? https://www.ptsd.va.gov/understand/common/common_adults.asp

²Wisco et al. *J Clin Psychiatry*. 2014.75(12):1338-46



TNX-102 SL for ASR/ASD: Program Status

Status: Expect to start investigator-initiated Phase 2 in 3Q 2024

Investigator-initiated Phase 2 Trial Funded by DoD grant to University of North Carolina (UNC)

- UNC Institute for Trauma Recovery awarded a \$3M grant from the Department of Defense (DoD)
- OASIS trial will build upon infrastructure developed through the UNC-led, \$40M AURORA initiative
 - AURORA study is a major national research initiative to improve the understanding, prevention, and recovery of individuals who have experienced a traumatic event
 - Supported in part by funding from the National Institutes of Health (NIH) and the health care arm of Google’s parent company Alphabet
- Opportunity to investigate the correlation between motor vehicle collisions and the emergence of ASD and PTSD
- Supported by multiple clinical trials:
 - Phase 2 trial in military-related PTSD (AtEase or NCT02277704)
 - Phase 3 trial in military-related PTSD (HONOR or NCT03062540)
 - Phase 3 trial in primarily civilian PTSD (RECOVERY or NCT03841773)
- In each of these studies, early and sustained improvements in sleep were associated with TNX-102 SL treatment by the PROMIS sleep disturbance (SD) scale and the Clinician Administered PTSD Scale (CAPS-5) “sleep disturbance” item.

Together these studies provide preliminary evidence that TNX-102 SL is well-tolerated and may promote recovery from PTSD via a pharmacodynamic facilitation of sleep-dependent emotional memory processing



TNX-102 SL for ASR/ASD: Phase 2 OASIS Study Design

General study characteristics:

- Randomized, double-blind, placebo-controlled study in Acute Stress Reaction (ASR) / Acute Stress Disorder (ASD)
- The proposed Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients presenting to the emergency department after a motor vehicle collision (MVC)
- The trial will enroll approximately 180 individuals who acutely experienced trauma at study sites across the US
- Participants will be randomized in the emergency department to receive a two-week course of either TNX-102 SL or placebo
- Investigator-initiated IND

Objective:

- Investigate the potential of Tonix’s TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to reduce the frequency and severity of the adverse effects of traumatic exposure, including acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD).
- ASR refers to the body’s immediate response to trauma, whereas ASD is the short-term effects of trauma (within 1 month), and PTSD is the long-term effects of trauma (beyond 1 month)

TNX-102 SL once-daily at bedtime
5.6 mg (2 x 2.8 mg tablets)*

Placebo once-daily at bedtime



*First dose of TNX-102 SL 5.6 mg versus placebo taken in the emergency department, and then daily at bedtime to finish 2 weeks of treatment

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With ASR/ ASD (OASIS)

- Primary outcome measure: Acute Stress Disorder Scale (ASDS) assessed at 7 and 21 days post MVC
- Posttraumatic stress symptom severity assessed at 6 and 12 weeks post MVC using the PTSD Checklist for DSM-5 (PCL-5)
- Standardized survey instruments of sleep disturbances, anxiety and depression symptoms, general physical and mental health, and clinical global improvement also employed
- Detailed and brief neurocognitive assessments are performed from baseline to 12 weeks after MVC at specific timepoints throughout study participation period

Fibromyalgia and Long-COVID



Significant Overlap between Fibromyalgia and Long-COVID

National Institutes of Health (NIH)-sponsored RECOVER study found many Long COVID patients suffer from pain at multiple sites¹

- Suggests that many Long-COVID patients may meet the diagnostic criteria for fibromyalgia

Tonix has previously presented its analysis of real-world evidence from the TriNetX claims database suggesting that ***over 40% of Long COVID patients present with a constellation of symptoms that overlap with fibromyalgia***^{2,3}

¹Thaweethai T, et al. *JAMA*. 2023 329(22):1934-1946.

²Feb 22, 2023 Tonix Pharmaceuticals Press Release. URL: <https://ir.tonixpharma.com/news-events/press-releases/detail/1369/tonix-pharmaceuticals-describes-emerging-research-on-the>

³September 21, 2022, Tonix Pharmaceuticals Poster at the IASP, "Retrospective observational database study of patients with Long COVID with multi-site pain, fatigue and insomnia".

URL: www.tonixpharma.com/wp-content/uploads/2022/09/Retrospective-Observational-Database-Study-of-Patients-with-Long-COVID-with-Multi-Site-Pain-Fatigue-and-Insomnia_A-Real-World-Analysis-of-Symptomatology-and-Opioid-Use.pdf



NASEM Definition of Long-COVID

- In June 2024, the US National Academies of Sciences, Engineering and Medicine (NASEM) described **fibromyalgia as a ‘diagnosable condition’ in people suffering from Long COVID¹**
- This definition provides guidance to government, healthcare professionals and industry that fibromyalgia can arise after infection with the SARS-CoV-2 virus and can be diagnosed in Long COVID patients

Fibromyalgia prevalence prior to COVID-19 pandemic: >10M adults in the US²

Long-COVID prevalence: 5.3% or ~14M adults in the US³

Tonix believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL as compared to market estimates from before the COVID-19 pandemic

¹U.S. National Academies of Sciences, Engineering, and Medicine. 2024. *A Long COVID Definition: A chronic, systemic disease state with profound consequences*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/27768>. <http://www.nationalacademies.org/long-covid-definition>.

²Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002

³National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey, 2022–2024. Long COVID. Generated interactively: July 22, 2024 from <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>

NASEM Language Highlighted by Senate Labor-HHS Appropriations Subcommittee (August 1, 2024)



“Long COVID Treatments.—The Committee remains concerned about the economic and overall health impact that Long COVID inflicts on the Nation. It is currently estimated that between 6 percent and 19 percent of those infected with SARS–CoV–2 go on to develop Long COVID, resulting in up to 20 million Americans suffering from this set of debilitating chronic symptoms. Long COVID is characterized by a wide range of symptoms including severe fatigue, non-restorative sleep, cognitive dysfunction, and widespread pain. Further, it resembles other post-acute infection syndromes [PAISs], such as fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS] and related conditions, known as 146 chronic overlapping pain conditions [COPCs] or nociplastic syndromes. While the Committee is pleased that NIH’s HEAL and RECOVER initiatives plan to target some specific symptoms of Long COVID, the Committee is concerned that NIH has not expanded the evaluation of treatments to address many common symptoms associated with Long COVID either individually or that present as syndromes which are combinations of symptoms. Furthermore, NIH’s research program has defined Long COVID narrowly, excluding many of the common symptoms plaguing Long COVID sufferers. In June 2024, NASEM released the 2024 NASEM Long COVID Definition, which encompasses extensive lists of the symptoms and diagnosable conditions that current science attributes to Long COVID. The Committee urges NIH to rebalance its research program to prioritize clinical trials in pursuit of effective treatments and to use the NASEM Long COVID definition to guide its choice of symptoms and conditions to be addressed by the candidate treatments. Such trials should target key symptoms and symptom complexes associated with Long COVID including widespread pain, fatigue, non-restorative sleep, brain fog, dizziness, post-exertional malaise [PEM], postural orthostatic tachycardia syndrome [POTS] and loss of taste and smell. Further, the Committee urges NIH to prioritize the support of clinical trials evaluating therapies for Long COVID including therapies that have demonstrated efficacy in treating COPCs or nociplastic syndromes that overlap with Long COVID.”

- Senate Appropriations Committee report on FY25 Labor, Health, and Human Services Appropriations Act includes language on Long COVID, fibromyalgia and nociplastic syndromes¹



¹FY25 Labor-HHS Senate Report, p145-146. Accessed Aug 7, 2024: <https://www.appropriations.senate.gov/download/fy25-lhhs-senate-report>



THANK YOU



APPENDIX

TNX-102 SL: RALLY Study

Increased Adverse Event-Related Discontinuations



Increases in AE-Related discontinuations in RALLY study compared with RELIEF study in both placebo and TNX-102 SL groups

	RALLY (F306)	RELIEF (F304)	RALLY (F306)	RELIEF (F304)
	Placebo		TNX-102 SL	
Patients with at least one TEAE leading to early discontinuation	6.2%	3.5%	15.2%	8.5%
Ratio of patients with at least one TEAE leading to early discontinuation in F306 to F304 (F306/F304)	1.77		1.79	

TEAE = treatment-emergent adverse event



Adverse events in RALLY

- TNX-102 SL 5.6 mg was well tolerated.
- Among participants randomized to drug and placebo groups, 73.8% and 81.4%, respectively, completed the 14-week dosing period.
- As expected, based on prior TNX-102 SL studies, oral administration site reactions were higher in the drug treatment group, including rates of tongue/mouth numbness, pain/discomfort of tongue/mouth, and product taste abnormal (typically a transient bitter aftertaste)
- Tongue/mouth numbness or tingling and product aftertaste were local effects nearly always temporally related to dose administration and transiently expressed (<60 minutes) in most occurrences.
- Adverse events resulted in premature study discontinuation in TNX-102 SL and placebo groups at rates of 15.2% and 6.2%, respectively
- Approximately 95% of adverse events in both the drug treatment and placebo groups were rated as mild or moderate.



TNX-102 SL: RALLY Study

Impact of Missing Data on *p*-Values in RALLY

Since 2010, FDA has generally required that “missing data” be accounted for by using a statistical method called “multiple imputation” or MI

- MI data approach can attenuate *p*-values in the setting of missing data

RALLY (F306) results without MI treatment for missing data are comparable to prior statistically significant RELIEF (F304) study

- Efficacy results in the table without MI are labelled “MMRM”

MI missing data treatment attenuated *p*-values in RALLY

- At the current time, we expect MI will be part of the statistical analysis for the RESILIENT trial

Endpoints	RALLY (F306)			
	MMRM+MI*		MMRM**	
	LSMD (SE)	<i>p</i> -value	LSMD (SE)	<i>p</i> -value
Pain by Diary#	-0.2 (0.16)	0.115	-0.4 (0.16)	0.014
FIQR Symptom domain	-1.9 (1.52)	0.216	-3.4 (1.55)	0.030
FIQR Function domain	-0.4 (1.46)	0.797	-1.6 (1.48)	0.266
PROMIS Sleep Disturbance	-2.3 (0.80)	0.004	-3.3 (0.73)	<0.001
PROMIS Fatigue	-1.2 (0.74)	0.101	-2.0 (0.73)	0.007
Sleep Quality by Diary	-0.3 (0.16)	0.094	-0.4 (0.16)	0.008
Endpoints	RELIEF (F304)			
	MMRM+MI*		MMRM**	
	LSMD (SE)	<i>p</i> -value	LSMD (SE)	<i>p</i> -value
Pain by Diary#	-0.4 (0.16)	0.010	-0.5 (0.16)	0.004
FIQR Symptom domain	-4.3 (1.60)	0.007	-5.6 (1.60)	<0.001
FIQR Function domain	-4.4 (1.69)	0.009	-5.2 (1.63)	0.001
PROMIS Sleep Disturbance	-2.9 (0.82)	<0.001	-3.3 (0.82)	<0.001
PROMIS Fatigue	-1.8 (0.76)	0.018	-2.1 (0.79)	0.007
Sleep Quality by Diary	-0.6 (0.17)	<0.001	-0.7 (0.17)	<0.001

FIQR = Fibromyalgia Impact Questionnaire-Revised; LSMD = least squares mean difference (between TNX-102 SL and placebo); MMRM = mixed model repeated measures; MI = multiple imputation; PROMIS = Patient-Reported Outcomes Measurement Information System; SE = standard error

* MMRM with MI was the pre-specified primary analysis

**MMRM without MI was a pre-specified analysis


Primary efficacy endpoint: change from baseline in the weekly average of daily diary pain severity numerical rating scale scores

Chronic Overlapping Pain Conditions (COPC) Believed to Result from Shared Brain Processes



- COPC is a set of disorders that co-aggregate; these disorders can include but are not limited to^{1,2}:

- Temporomandibular disorder
- Fibromyalgia
- Irritable bowel syndrome
- Vulvodynia
- CFS/ME³
- Interstitial cystitis/painful bladder syndrome



- Endometriosis
- Chronic tension-type headache
- Migraine headache
- Chronic lower back pain

- Similar central mechanisms play significant roles in all pain conditions, even those with known peripheral contributions^{1,2}

¹Maixner W, et al. *J Pain*. 2016;17(9 Suppl):T93-T107.

²Veasley C, et al. http://www.chronicpainresearch.org/public/CPRA_WhitePaper_2015-FINAL-Digital.pdf. Published May 2015. Accessed July 26, 2021.


³CFS/ME – chronic fatigue syndrome/myalgic encephalomyelitis



The Third Primary Type of Pain: Nociplastic Pain¹⁻⁴

Nociplastic syndrome includes:

- (1) widespread pain
- (2) fatigue
- (3) sleep disturbances
- (4) cognitive dysfunction (“brain fog”)



¹Trouvin AP, et al. *Best Pract Res Clin Rheumatol.* 2019;33(3):101415.

²Fitzcharles MA, et al. *Lancet* 2021;397:2098-110

³Kaplan CM, et al. *Nat Rev Neurol.* 2024 20(6):347-363..

⁴Clauw DJ. *Ann Rheum Dis.* 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.



Fibromyalgia is Believed to Result from Chronic Pain or Prior Stress Experiences¹⁻²

The pain system evolved to detect acute pain

- The body's "check engine" light

Chronic pain breaks down the system that determines whether a sensory experience is painful

- Chronic pain results in nociplastic syndromes
- Nociplastic syndrome was formerly known as "Central and Peripheral Sensitization"

Chronic Overlapping Pain Conditions (COPCs) are Nociplastic Syndromes:

- Fibromyalgia
- ME/CFS
- Migraine
- Irritable Bowel Syndrome
- Endometriosis
- Low Back Pain

Stresses that may precede or precipitate FM include:

Chronic nociceptive pain

- e.g., osteoarthritis

Chronic neuropathic pain

- e.g., diabetic neuropathy

Infectious

- e.g., viral illness

Cancer

- e.g., breast cancer

Chemical

- e.g., cancer chemotherapy

Traumatic

- e.g., motor vehicle accident

Physiologic

- e.g., disturbed sleep

¹Kaplan CM, et al. *Nat Rev Neurol*. 2024 20(6):347-363..

²Clauw DJ. *Ann Rheum Dis*. 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.



Common Chronic Conditions are a Challenge for Pharma

Fibromyalgia is a common chronic disease¹⁻³

- Chronic pain syndrome that persists for years or decades

No animal model is recognized for nociplastic syndromes or its component symptoms

- Widespread pain
- Fatigue
- Sleep disturbance
- Cognitive impairment

Nociplastic symptoms are subjective

- Humans need to report symptoms using scales

Clinical trials measuring subjective symptoms are challenging

- Placebo response is typically observed
- Long-term therapy means requires long-term tolerability

¹The U.S. Centers for Disease Control defines chronic diseases as “conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both.”

www.cdc.gov/chronicdisease/about/index.htm. (accessed Jan 28, 2024)

²Kaplan CM, et al. *Nat Rev Neurol*. 2024 20(6):347-363..

³Clauw DJ. *Ann Rheum Dis*. 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.



Common Chronic Conditions are a Challenge for Society

The Opiate Crisis in the U.S. was driven by mistreatment of chronic pain, which was often nociplastic pain

- The epidemic of prescription pain killers was addressed by regulations which limited the availability of opiates
- Many individuals who are opiate dependent have transitioned to illegal street heroin and fentanyl
- Illegal drugs contribute to homelessness

There is an unmet need for non-opiate analgesics that address nociplastic pain


- No new drug for fibromyalgia has been approved since 2009



Central Sensitization (CS)

A Feature of Many Nociceptive Pain Syndromes

- CS is caused by amplified neural signaling in CNS pain circuits¹⁻³
- Patients with CS perceive higher pain to a slightly noxious stimuli than in non-CS individuals (hyperalgesia)¹
- Severe CS can lead to hypersensitivity to stimuli that are not typically painful (allodynia)²
- CS varies in severity and is observed in syndromes including FM and ME/CFS^{1,3}



¹CFS/ME – chronic fatigue syndrome/myalgic encephalomyelitis

²FM - fibromyalgia

³Nijs J, et al. *Lancet*. 2021;3(5):e383-e392.

Central Sensitization (CS)

Can Occur in a Range of Diseases and Conditions



Degree of central sensitization

